NEW YORK (GenomeWeb) – San Sebastián, Spain-based Patia has signed an exclusive deal with Premier Medical Laboratory Services to offer a type 2 diabetes risk assay in the US.
The deal will make Greenville, South Carolina-based Premier the only lab in the US to offer the DiabetesPredict test, a representative confirmed.
DiabetesPredict combines a genetic risk analysis with behavioral and lifestyle assessments. The genetic test uses Thermo Fisher Scientific's TaqMan OpenArray for genotyping, and includes 16 SNPs that have been associated with type 2 diabetes in a variety of ethnicities, including Caucasian, Latin American, African, and Asian populations.
A patient's report then provides diet, exercise, and lifestyle recommendations that are informed by the genetic profile, and Patia also offers "integrated wearable pedometers, smartphone, and web-based apps and games to aid these patients in their treatment plan and to help ensure that they stay on track," according to a statement.